Acute nicotinic acid (NiAc) administration results in rapid reduction of plasma free fatty acid (FFA) concentrations. However, sustained NiAc exposure is associated with tolerance development resulting in return of FFA to pre-treatment levels. The aim of this study was to determine whether a 12h rectangular exposure profile (intermittent dose group) could avoid tolerance development and thereby reverse insulin resistance induced by lipid-overload. FFA lowering was assessed in male Sprague Dawley (Lean) and obese Zucker rats (Obese) in response to a 5h NiAc infusion, in either NiAc-naïve animals, or after 5 days of continuous (24h/day) or intermittent (12h/day) NiAc dosing (via implantable, programmable mini-pump).
INTRODUCTION
Lipid overload in non-adipose tissues has been linked to the pathogenesis of insulin resistance and atherogenesis (1) (2) (3) (4) . A potential means for reversing peripheral lipid overload is to restrict the release of free fatty acids (FFA) from adipose tissues. A number of independent mechanisms have been explored and provide evidence supporting this concept. This includes inactivation of hormone sensitive lipase (HSL) (5, 6) and A 1 -adenosine receptor agonists (7) . In addition, several other G protein-coupled receptors (GPCRs) are involved in controlling adipocyte FFA release, including GPR43, GPR81 and GPR109A (8) (9) (10) .
The GPR109A agonist nicotinic acid (NiAc) has been used clinically ever since its anti-dyslipidemic effects (HDL elevation and reductions of; total cholesterol, LDL-cholesterol and TG) were discovered over 50 years ago (11) (12) (13) (14) (15) . Although NiAc potently lowers FFA acutely, large-scale clinical studies, with repeated oral NiAc administration, often report increased levels of fasting glycemia (16-19). NiAc has not been optimized to achieve durable and therapeutically meaningful FFA lowering. By this we specifically mean reducing around-theclock FFA area under the curve. In theory this might be achieved by sustained NiAc exposure however the FFA lowering effect seen initially appears to be lost over time despite maintained 
Study I (NiAc induced FFA lowering).
In the morning of the acute experimental day, the jugular catheter was connected to a swivel system to enable blood sampling in unrestrained animals. Jugular catheter patency was maintained by continuous infusion (5 µl min -1 ) of Nacitrate solution (20.6 mM). After a 3-4h adaptation period, at ~12:00h, the basal phase of the acute experiment (Basal Period) commenced with 2-3 blood samples drawn between -60 and -5 NiAc levels were below the detection limit (6 nM).
Free fatty acids
Plasma FFA concentration-time profiles are shown in Fig In the Lean NiAc naïve group, during the Post Infusion Period, there was clear evidence of a marked rebound ( Fig. 3 ) with FFA AUC greater than saline control for the same period (P<0.05, Fig 4B) . Interestingly, the Cont. NiAc group also exhibited a rebound ( 
Insulin and Glucose
Plasma insulin and glucose concentration-time profiles are shown in Fig respective saline controls, Fig. 7A ), suggesting an improvement in insulin sensitivity which was particularly remarkable in the obese groups. While insulin profiles in the different groups were broadly similar in pattern to the FFA profiles described above, one difference was in the Obese animals where the lowering of insulin AUC was fully preserved at 5 days in Inter. NiAc vs. NiAc naïve groups (P>0.05, Fig. 6A ), compared to FFA lowering which was partially lost at this time point (Fig. 4A ). The rebound phenomenon was not just restricted to FFA. Insulin rebounds were observed in all NiAc dosed groups (Fig 5A-B) with the exception of Obese Cont. NiAc (Fig. 5B) .
As for FFA (described above), reduction in insulin AUC achieved during the Infusion Period tended to be cancelled during the Post Infusion Period, with the result that total 8h insulin AUC is NiAc groups (P<0.001 vs. saline control, Table 2 ). The extent of FFA suppression was similar in NiAc naïve and Inter. NiAc groups (P>0.05).
Clamps were performed at similar levels of glycemia (Table 2) . Steady state glucose infusion rates (GIRs) needed to maintain basal glucose levels during the hyperinsulinemic-isoglycemic clamp are summarized in Fig. 8 . In the NiAc naïve group, GIR was markedly increased compared to saline infused controls (↑92%, P<0.01). Importantly, the Inter. NiAc group also had an 16 elevated GIR (↑71%, P<0.05), similar in magnitude to the NiAc naïve group (P>0.05), compatible with a sustained insulin sensitization of the intermittent dosing approach. In stark contrast, upon continuous dosing, this effect was completely lost (P>0.05 vs. saline control, Fig. 8 ). Across all groups, GIR was negatively correlated with prevailing clamp FFA levels;
individual data linear regression, r 2 =0.35, P<0.01 (data not shown).
Study III: NiAc induced changes in adipose tissue gene (mRNA) expression
Quantitative RT-PCR (Taqman) was conducted to assess whether changes in mRNA expression of adipocyte proteins could explain the differences observed in the NiAc-induced FFA lowering in Study I ( Table 3) Overall there was no evidence that a coordinated alteration in expression of genes was responsible for the tolerance development in either Lean or Obese (Table 3) .
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Liver triglycerides
Liver triglyceride (TG) content, at the end of the Infusion Period, is presented in 
DISCUSSION
The intermittent drug holiday approach succeeded in retaining the ability of a therapeutically relevant NiAc exposure to induce FFA lowering. In lean rats, following intermittent (12h on/12h off) infusions for 5 days, the acute NiAc-induced FFA suppression was completely preserved (Fig. 3 and 4) . While in the obese rats there was a partial loss of FFA lowering efficacy, following 5 days intermittent dosing, importantly, this did not appear to be progressive with similar FFA lowering at 11 vs. 5 days (Fig. 3 and 4) . (20) previously demonstrated, in Wistar rats, complete return of FFA to pre-treatment levels during a ~10-fold higher NiAc continuous infusion rate than we have used in the current study.
Based on a pharmacokinetic analysis (data not shown), and the fact that NiAc clearance exhibits saturation kinetics (26), we estimate that this infusion rate would result in plateau concentrations >20-fold above those achieved in the current study.
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Markedly improved insulin sensitivity was seen in association with NiAc induced FFA lowering, either in NiAc naïve or previously intermittently dosed obese Zucker rats. Adult male obese
Zucker rats exhibit extreme whole body insulin resistance associated with tissue lipid overload.
Elevated FFA mobilization from adipose tissue, seen under both basal fasting as well as hyperinsulinemic clamp conditions, is an important mechanism driving this condition (28, 31). In the present study, acute suppression of circulating FFA levels by NiAc in the Obese animals was associated with reduced fasting hyperinsulinemia (Fig. 6A) . Reduced insulin secretion might be explained by direct effects on the islets of either NiAc (32) or the fall in FFA level (33) .
However, if the effect was only to decrease insulin secretion then levels of glycemia should have increased, which was not the case (Fig. 7A) . Reduced fasting insulinemia in association with normoglycemia suggests instead that NiAc enhanced whole body insulin sensitivity. Indeed, this was confirmed by the elevated GIRs needed to maintain isoglycemia during the hyperinsulinemic clamps ( Fig. 8 and Table 2 ).
Rapid effects of acute modulation of FFA metabolism on insulin sensitivity have been previously reported. The acute blockade of β-oxidation, using etomoxir, increased insulin sensitivity in skeletal muscle and reduced gluconeogenesis (34, 35) whole body fat to carbohydrate oxidation, in association with the suppression of plasma FFA (38) . We were hoping to reverse lipid overload, not just by reducing acute circulating FFA, but also by lowering endogenous lipid stores via a reduction of net (24h average) FFA levels with the intermittent dosing protocol. Our quantitative AUC analysis (Fig. 4) suggests, however, that the FFA rebound is of a magnitude sufficient to cancel the acute NiAc induced FFA lowering in the intermittently dosed groups, despite the fact that this presumably only occurred once per day.
Failure of the intermittent dosing strategy to lower net FFA levels over the 5 day dosing period was also indicated by the lack of lowering of hepatic TG content (Table 4) ; a relatively slow turnover tissue lipid pool. This may well explain why the NiAc induced enhancement in GIR was similar in the previously intermittently dosed group compared to the naïve group, since reduced peripheral lipid availability was only effected through reduction of circulating FFA, and the degree to which plasma FFA level was lowered was similar in both groups. The critical role of acute FFA levels is also evidenced by the apparent lack of amelioration of insulin resistance (HOMA-IR) in the intermittent NiAc dose group in the basal state; a period when FFA levels were not reduced ( Table 2) .
Our results are reminiscent of studies of the nicotinic acid analog, acipimox, in patients with type 2 diabetes. Thus in association with FFA lowering, acipimox acutely enhanced whole body insulin sensitivity in patients naïve to the drug (via a selective increase in oxidative glucose Further refinements to NiAc dosing might achieve greater lipid lowering and insulin sensitization. As discussed above, the simple intermittent protocol for infusion of NiAc has probably not succeeded in lowering average daily FFA levels, with the rebound rise in FFA occurring rapidly in response to NiAc withdrawal quantitatively cancelling the FFA lowering during NiAc infusion, resulting in no reduction of hepatic tissue lipid storage. We anticipate that further refinements of the infusion protocol or optimal timing of NiAc administration relative to food intake might mitigate this issue. Thus a programmed, more gradual decline in NiAc concentrations to terminate each infusion period might help to minimize the rebound.
Alternatively, FFA rebound might be minimized if NiAc withdrawal is timed to occur in association with feeding/insulin administration. This might especially be the case if the proposal that FFA rebound involves a counter-regulatory response (42) to defend substrate supply is correct. Whatever the specific strategy, the current experimental paradigm combining a translationally relevant preclinical disease model, chronically catheterized for repeated stress free blood sampling, the programmable/implantable pump to deliver nicotinic acid with its desirable properties of high potency, high solubility and rapid clearance, provides a useful experimental paradigm to explore alternative protocols in order to reveal the potential of FFA lowering to improve glucose control.
How do we resolve our data with the general view that NiAc dosing in man worsens glucose control? Current study limitations, either species differences or the relatively short duration compared to the long-term treatments in the clinic, might provide trivial explanations. However, we suggest that the timing of NiAc administration and assessment of FFA level, glucose control or insulin sensitivity may be critical. In particular, we assessed insulin sensitivity in the presence of circulating levels of NiAc sufficient to suppress FFA. This differs from almost all clinical reports where assessments are made when circulating NiAc levels are likely to be very low (overnight fasting, last dose taken at bedtime the night before) e.g. when NiAc was orally dosed 12h before clamp studies, FFA rebound was associated with insulin resistance (25). We are not the first to suggest the potential impact of timing on niacin therapy. Usman et al. (44) proposed that giving ER niacin at meal time, instead of bed time, could improve triglyceride lowering.
Based on the current results it seems reasonable that this strategy might also improve glucose handling following mixed meal ingestion.
An intermittent NiAc exposure profile equivalent to the one used in the present study, with stable and sufficient NiAc levels to suppress FFA 12h/day, has to our knowledge not been applied in the dosing is also associated with significant FFA rebound (e.g. (42)).
In conclusion, an intermittent nicotinic acid dosing strategy succeeded in retaining FFA lowering and improving insulin sensitivity in obese Zucker rats. While these data suggest that FFA lowering is sufficient to improve insulin sensitivity, further refinements to the administration regime should be explored to more profoundly reverse lipid-overload induced insulin resistance. 
